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A B S T R A C T
Purpose
Risk-reducing salpingo-oophorectomy (RRSO) lowers mortality from ovarian/tubal and breast
cancers among BRCA1/2 mutation carriers. Uncertainties persist regarding potential benefits of
RRSO among high-risk noncarriers, optimal surgical age, and anatomic origin of clinically occult
cancers detected at surgery. To address these topics, we analyzed surgical treatment arm results
from Gynecologic Oncology Group Protocol-0199 (GOG-0199), the National Ovarian Cancer
Prevention and Early Detection Study.
Participants and Methods
This analysis included asymptomatic high-risk women age  30 years who elected RRSO at
enrollment. Women provided risk factor data and underwent preoperative cancer antigen 125
(CA-125) serum testing and transvaginal ultrasound (TVU). RRSO specimens were processed
according to a standardized tissue processing protocol and underwent central pathology panel
review. Research-based BRCA1/2 mutation testing was performed when a participant’s mutation
status was unknown at enrollment. Relationships between participant characteristics and diag-
nostic findings were assessed using univariable statistics and multivariable logistic regression.
Results
Invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966
RRSOs (BRCA1 mutation carriers, 4.6%; BRCA2 carriers, 3.5%; and noncarriers, 0.5%; P  .001).
In multivariable models, positive BRCA1/2 mutation status (P  .0056), postmenopausal status
(P  .0023), and abnormal CA-125 levels and/or TVU examinations (P  .001) were associated with
detection of clinically occult neoplasms at RRSO. For 387 women with negative BRCA1/2
mutation testing and normal CA-125 levels, findings at RRSO were benign.
Conclusion
Clinically occult cancer was detected among 2.6% of high-risk women undergoing RRSO.
BRCA1/2 mutation, postmenopausal status, and abnormal preoperative CA-125 and/or TVU were
associated with cancer detection at RRSO. These data can inform management decisions among
women at high risk of ovarian/tubal cancer.
J Clin Oncol 32:3275-3283. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Risk-reducing salpingo-oophorectomy (RRSO) re-
duces number of deaths resulting from ovarian/
tubal and breast cancers among carriers of
deleterious BRCA1/2 mutations and thus has be-
come a preferred management strategy for these
women.1-3 Although oral contraceptive use and
tubal ligation reduce the risk of ovarian/tubal neo-
plasms, level of protection is lower than that
achieved with RRSO, and breast cancer risk is not
reduced.4-7 The effectiveness of screening in reduc-
ing mortality attributable to these cancers remains
unproven. Annual concurrent cancer antigen 125
(CA-125) serum testing and transvaginal ultra-
sound (TVU) in the Prostate, Lung, Colorectal and
Ovarian trial did not reduce ovarian/tubal cancer
mortality.8 Preliminary results from the UK Collab-
orative Trial of Ovarian Cancer Screening, which
targeted similar women, reported potentially better
results using algorithm-based CA-125 testing with
secondary TVU examination9; final results are
pending, and data from high-risk women are just
emerging.10 Thus, determining which women
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benefit most from RRSO and the age at which surgery provides max-
imum protection with minimum adverse effects from hormone de-
privation remains critical.11-13
Clinical acceptance of RRSO has provided pathologists with
opportunities to study small ovarian/tubal neoplasms, prompting
new insights into their pathogenesis. We now know that many
high-grade serous cancers, the numerically predominant and most
lethal subtype of ovarian/tubal cancer, arise from the fallopian tube
fimbria, not the ovary, as previously supposed.14-19 This has
prompted discussions of a two-stage prevention strategy in which
salpingectomy with ovarian retention would be performed in
younger women, followed by oophorectomy at a later time.20
However, this approach remains investigational.21-23
The reported frequency of clinically occult neoplasms in RRSO
varies widely, reflecting differences in study populations, pathology
processing, and diagnosis.2,16,24-55 Prior reports are characterized by
small size, incomplete risk factor information (eg, missing BRCA1/2
data), variable preoperative clinical testing assessment, differences in
symptomatic disease exclusion criteria, and retrospective analysis of
nonstandardized pathology diagnoses. The prevalence of occult neo-
plasms at RRSO in six prospective studies34,40,47-49,55 averages as fol-
lows: all BRCA-positive participants, 3.7%; BRCA1 positive, 4.4%;
BRCA2 positive, 2.0%; and high-risk/mutation-negative/unknown
status, 0.5% (Data Supplement). The literature includes only approx-
imately 150 reports of occult cancers at RRSO, most from retrospec-
tive studies. Accordingly, we now report results from the surgical
intervention arm of Gynecologic Oncologic Group (GOG) Protocol-
0199 (GOG-0199), the Prospective Study of Risk-Reducing Salpingo-
Oophorectomy and Longitudinal CA-125 Screening Among Women
at Increased Genetic Risk of Ovarian Cancer (also known as National
Ovarian Cancer Prevention and Early Detection Study).56 GOG-0199
is a nonrandomized multicenter trial of women at high-risk of ovari-
an/tubal neoplasia comparing health outcomes among women who
chose between RRSO or screening (CA-125– and TVU-based testing,
according to risk of ovarian cancer algorithm).57
PARTICIPANTS AND METHODS
Participants
Eligible participants included women age  30 years who were at high
risk of developing ovarian/tubal/primary peritoneal cancer based on being
BRCA1/2 mutation positive or having a strong family history (specified else-
where56), not clinically suspected of having a gynecologic cancer, and being
managed with preventive rather than therapeutic intent.56 Given the low
screening test sensitivity and specificity of CA-125 and TVU, normal results for
these tests were not required for eligibility. Candidate participants with abnor-
malities considered insufficient to merit a workup for cancer were included. At
enrollment, participants elected immediate RRSO or screening, with the op-
tion to cross over to the RRSO arm postenrollment, either electively or for
indications. From June 2003 to November 2006, 1,575 and 1,030 women were
enrolled onto the screening and RRSO arms, respectively; 28 had unconfirmed
eligibility, and 36 not undergoing RRSO per protocol were excluded, leaving
966 eligible surgical participants (Fig 1). Protocol NCT-00049049 was ap-
proved by institutional review boards at the National Cancer Institute, GOG,
and 151 GOG institutions (United States and Australia).
Baseline Study Procedures
Participants completed ovarian/tubal cancer risk factor, medical history,
quality-of-life, and medical decision-making questionnaires; donated blood
for serum and DNA; and underwent CA-125 testing and TVU before RRSO.
Mutation status was known for 962 (99.6%) of 966 participants, from clinical
and research-based mutation testing.56 Women electing RRSO underwent
surgery within 90 days of enrollment, with intraoperative pelvic organ visual
inspection, peritoneal lavage cytology, and total removal of both ovaries and
fallopian tubes. Hysterectomy was performed electively, per patient and phy-
sician discretion.
Pathology Processing and Panel Review
The protocol stipulated that ovaries and fallopian tubes be sectioned at 2-
to 3-mm intervals and entirely submitted for histologic examination (reported
as done in 85% of pathology reports). Medians of 16, 17, and 15 slides (each
potentially containing multiple sections) per RRSO were submitted for
BRCA1 mutation carriers, BRCA2 mutation carriers, and noncarriers, respec-
tively. Centers enrolling  20 participants submitted a median of 15 slides per
RRSO versus 17 for higher enrolling centers.
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  Lacked sufficient personal or family (n = 48)
    history to meet high-risk criteria
  Had inadequate data (n = 67)
  Did not meet other entry criteria (n = 1)
)46 = n( dedulcxE
  Lacked sufficient personal or family (n = 24)
    history to meet high-risk criteria
  Did not undergo RRSO (n = 36)
  Did not meet other entry criteria (n = 4)
ROCA patients: evaluable for cancer 
screening end points
(n = 1,459)
RRSO patients: evaluable for cancer prevalence
end points at baseline surgery
(n = 966)
Subject of a separate analysis No cancer at RRSO (n = 942)
“Ovarian” cancers at RRSO (n = 25)
    Ovarian carcinoma (n = 11)
    Fallopian tube carcinoma (n = 9)
    Primary peritoneal carcinoma (n = 5)
Fig 1. CONSORT diagram for GOG (Gy-
necologic Oncology Group) 0199, the Na-
tional Ovarian Cancer Prevention and Early
Detection Study. ROCA, risk of ovarian
cancer algorithm; RRSO, risk-reducing
salpingo-oophorectomy.
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Hematoxylin and eosin–stained surgical pathology slides from 957
(99.1%) RRSOs and cytopathology slides of peritoneal washes from 881
(91.2%) were initially reviewed (M.E.S.) to identify cancer and determine its
primary site, histologic subtype, grade, and extent. RRSOs showing serous
tubal intraepithelial carcinoma (STIC) associated with invasive cancer were
designated as primary fallopian tube cancers; primary sites of the remaining
cancers were assigned based on distribution and extent of tumor deposits.
Grading and staging were performed according to the International Federa-
tion of Gynecology and Obstetrics classification. Cases initially classified as
invasive cancer, STIC, or tubal atypia of any severity were reviewed indepen-
dently by a second pathologist (O.B.I.) and then jointly reviewed to resolve
discrepancies. Final diagnoses were assigned in a consensus review conducted
by three pathologists (M.E.S., O.B.I., B.M.R.), masked to prior diagnoses. Our
analysis is limited to cases with consensus diagnosis of STIC or invasive cancer.
Statistical Methods
Frequencies and percentages with 95% CIs of invasive cancer and STIC
were defined overall and by specific participant characteristics: pertinent med-
ical history, including race, age, menopausal status, family history of breast and
ovarian cancer, BRCA1/2 mutation status, personal history of breast cancer,
use of oral contraceptives or menopausal hormones, parity, tamoxifen use,
and preoperative testing, including CA-125 levels (upper normal: premeno-
pausal, 50 U/mL; postmenopausal, 35 U/mL), TVU results, and test combina-
tions.58 The primary outcome for this analysis was STIC or invasive ovarian/
tubal/peritoneal cancer, referred to herein as ovarian/tubal neoplasm. Single-
factor associations between categorical variables and frequency of ovarian/
tubal neoplasms were assessed with Fisher’s exact tests; associations for age as
a continuous variable were evaluated using nonparametric Kruskal-Wallis
tests. To assess factors independently associated with pathologic findings, we
performed multivariable logistic regression; the outcome variable was detec-
tion of ovarian/tubal neoplasm, and explanatory variables included specific
factors that were included in the final model, using stepwise forward selection
at levels of P  .05.
RESULTS
Prevalence of Invasive Cancer and STIC by
Participant Characteristics
Characteristics among BRCA1 mutation carriers, BRCA2 muta-
tion carriers, and noncarriers were identical for all but three factors:
ovarian cancer family history (BRCA1 carriers, 55.0%; BRCA2 carri-
ers, 33.2%; and noncarriers, 57.7%; P  .001), menopausal hormone
use (BRCA1 carriers, 61.3%; BRCA2 carriers, 51.6%; and noncarriers,
44.2%; P  .001), and tamoxifen use (BRCA1 carriers, 17.9%; BRCA2
carriers, 27.4%; and noncarriers, 32.8%; P  .001).
Among 966 participants, 25 (2.6%; 95% CI, 1.6% to 3.6%) were
diagnosed with ovarian/tubal neoplasms, including 15 of 326 BRCA1
mutation carriers (4.6%; 95% CI, 2.3% to 6.9%), eight of 231 BRCA2
carriers (3.5%; 95% CI, 1.1% to 5.8%), and two of 403 noncarriers
(0.5%; 95% CI, 0.2% to 1.2%; P  .001). These 25 participant cases
included four STICs (BRCA1, n  2; BRCA2, n  2).
Women with ovarian/tubal neoplasms were older than those
with benign pathology (age 52.7 v 47.1 years; P  .001; Table 1).
Neoplasms were detected among 4.5% of postmenopausal women
versus 1.2% of premenopausal women (P .003). Past tamoxifen use,
but not personal history of breast cancer, was marginally associated
with ovarian/tubal neoplasm (P  .04). Ovarian/tubal neoplasms
were found among 10.6% of women with abnormal TVU and/or
elevated CA-125 level versus 1.6% of those with both tests normal,
a difference almost entirely attributable to elevated CA-125 results.
Neoplasms were detected among seven (26.9%) of 26 women with
abnormal CA-125 tests only, one (1.3%) of 77 women with abnor-
mal TVU only, three (25.0%) of 12 women with both tests abnor-
mal, and 13 (1.6%) of 818 women with normal results for both tests
(P  .001; Table 1). Among BRCA mutation–negative women, 15
(3.7%) of 402 had abnormal CA-125 levels; neoplasms were not
Table 1. Characteristics of Women Undergoing RRSO in GOG-0199: National








PNo. % No. %
Baseline CA-125/TVU  .001
Normal/normal 805 88.6 13 54.0
Abnormal/normal 19 2.1 7 29.2
Normal/abnormal 76 8.4 1 4.2
Abnormal/abnormal 9 1.0 3 12.5




Premenopausal 559 59.4 7 28.0
Postmenopausal 382 40.6 18 72.0
Race NS
White 892 95.3 24 96.0
Black 32 3.4 1 4.0
Other 12 1.3 0 0.0
Nulliparous NS
No 700 85.0 15 71.4
Yes 124 15.0 6 28.6
Family history
Breast cancer NS
No 153 16.8 1 4.4
Yes 755 83.2 22 95.6
Ovarian cancer NS
No 444 49.0 13 56.5
Yes 463 51.0 10 43.5
BRCA mutation status†  .001
Noncarrier 401 42.3 2 8.0
BRCA1 positive 311 33.3 15 60.0
BRCA2 positive 223 23.8 8 32.0
Double positive 2 0.2 0 0.0
OC use NS
Current 51 5.4 0 0.0
Former 630 67.2 15 60.0
Never 257 27.4 10 40.0
Menopausal hormone use NS
Current 165 18.2 1 4.4
Former 269 29.7 11 47.8
Never 471 52.0 11 47.8
Personal history of breast cancer NS
No 421 44.7 10 40.0
Yes 520 55.3 15 60.0
Tamoxifen use .04
Current 119 13.2 0 0.0
Former 120 13.3 6 26.1
Never 666 73.6 17 73.9
Abbreviations: CA-125, cancer antigen 125; GOG, Gynecologic Oncology
Group; IQR, interquartile range; NS, not significant; OC, oral contraceptive;
RRSO, risk-reducing salpingo-oophorectomy; STIC, serous tubal intraepithelial
carcinoma; TVU, transvaginal ultrasound.
Numbers might not add up to total of 966 because of missing values.
†Two participants with both BRCA1 and BRCA2 mutations were excluded
from this analysis.
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observed among 387 mutation-negative participants with normal
baseline CA-125.
CA-125 levels  100 U/mL were recorded for 14 women (one
with a suspicious TVU), including seven with cancers detected at
RRSO (ovarian, n  4; peritoneal, n  2; and tubal primary, n  1).
Twelve cancers (BRCA1, n8; BRCA2, n2; and noncarriers, n2)
occurred among the 116 women with a TVU abnormality and/or
CA-125 elevation. After excluding these 116 participants, the remain-
ing 13 prevalent cancers occurred among 496 BRCA1/2 mutation
carriers versus none of the 350 noncarriers.
In multivariable models, postmenopausal status (odds ratio
[OR], 4.8; 95% CI, 1.8 to 13.2), positive BRCA1/2 mutation test (OR,
8.3; 95% CI, 1.9 to 37.0), and abnormal CA-125 and/or TVU results
(OR, 13.8; 95% CI, 5.2 to 36.3) were independently associated with
ovarian/tubal neoplasm at RRSO. In models excluding 27 women
with suspicious TVUs and/or CA-125 levels  100 U/mL, factors
associated with neoplasms included: BRCA1/2 mutation (OR, 11.3;
95% CI, 1.4 to 87.9), abnormal baseline test (OR, 6.5; 95% CI, 1.8 to
24.3), and menopausal status (OR, 4.0; 95% CI, 1.2 to 13.3). Cancers
were not observed among noncarriers with normal baseline tests;
among carriers, older age and postmenopausal status were associated
with a similar level of minimal risk (OR, 1.1; 95% CI, 1.0 to 1.1).
Clinical Characteristics of Invasive Cancers and STICs
in GOG-0199
The neoplasms detected at RRSO were classified as ovarian (n 
10), tubal (n  10), and primary peritoneal (n  5). Among 21
invasive cancers, 13 were serous, two were endometrioid, and six were
mixed/unclassifiable histologic type (Table 2). Fourteen neoplasms
were stages 0 to II, including five ovarian and nine tubal primaries
(four STICs), of which 11 showed minimal disease volumes ( 1 cm),
and three demonstrated macroscopic ovarian cancer (Fig 2). Women





(U/mL ) Tumor Volume
Ovary
BRCA1
Serous adenocarcinoma 44 Positive IIIC 110 Multiple ovarian and peritoneal nodules
44 Positive IIIC 158 8-cm mass in right ovary
46 Negative IIA 28 2.7-cm mass in right ovary
58 Missing IIIC 1,128 6-cm friable mass in left ovary; 3.8-cm mass in right ovary
Adenocarcinoma with squamous
differentiation
46 Positive IIIB 12 1.1-cm nodule in right ovary
Endometrioid adenocarcinoma 50 Negative IB 24 Microscopic foci in both ovaries
Mixed epithelial adenocarcinoma 52 Positive IIIC 336 Multiple omental implants and nodules
BRCA2
Serous adenocarcinoma 54 Positive IC 11 1-mm focus in left and right ovaries
55 Negative IC 12 2.2-cm nodule in right ovary; 1.5-cm nodule in left ovary identified on sectioning
Endometrioid adenocarcinoma 51 Negative IB 66 2-cm lobulated mass in left ovary identified on sectioning
Fallopian tube
BRCA1
Serous adenocarcinoma 42 Positive IIC 11 0.5-cm arising from fimbriated end of right FT; 0.25-cm focus on surface of
right ovary
61 Positive IIIC 974 5-cm mass in left FT
Adenocarcinoma 59 Negative IA 16 1-cm mass in fimbriated end of left FT
Serous tubal intraepithelial
carcinoma
48 Negative 0 20 Microscopic focus
58 Negative 0 14 Microscopic focus
BRCA2
Serous adenocarcinoma 71 Negative IA 20 Microscopic focus in left FT
55 Positive IIC ND Microscopic foci in ovaries and left FT
Serous tubal intraepithelial
carcinoma
56 Negative 0 8 Microscopic focus
55 Negative 0 11 Microscopic focus
BRCA mutation negative
Adenocarcinoma 73 Negative IA 67 Microscopic focus in left FT
Primary peritoneal
BRCA1
Serous adenocarcinoma 51 Positive IIIC 1,064 Numerous omental masses
60 Positive IIIC 20 Microscopic omental nodules and intraluminal papillary adenocarcinoma
Adenocarcinoma 47 Positive III 72 1.2-cm cul-de-sac nodule
BRCA2
Carcinoma NOS 52 Positive III 6 Microscopic focus in left ovary
BRCA mutation negative
Serous adenocarcinoma 50 Positive III 196 Microscopic foci in both ovaries
Abbreviations: FT, fallopian tube; ND, not done; NOS, not otherwise specified; RRSO, risk-reducing salpingo-oophorectomy.
Information on complete staging was available for only one of 14 early-staged participant cases; 2012 version of International Federation of Gynecology and
Obstetrics staging system was used.
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with stage I cancers presented a median CA-125 level of 20 U/mL
(range, 11 to 67 U/mL) versus 196 U/mL (range, 12 to 1,128 U/mL)
among those with stage III cancers. All cases of STIC occurred among
mutation carriers with normal CA-125 levels (range, 8 to 20 U/mL).
Peritoneal washes were positive in 14 (1.6%) of 881 cases of invasive
cancer, including 13 ovarian/tubal neoplasms and one endometrial
cancer (Table 2; Appendix Table A1, online only). All participant cases
with positive washes had cancer in surgical pathology specimens.
Among 515 women who underwent elective hysterectomy, six
(1.2%) harbored endometrial cancer, including two cases each of
uterine endometrioid and mucinous cancers among noncarriers and
two serous cancers among BRCA1 mutation carriers (Appendix Table
A1, online only).
DISCUSSION
Our results demonstrated ovarian/tubal neoplasms in 2.6% of RRSOs
(BRCA1 mutation carriers, 4.6%; BRCA2 mutation carriers, 3.5%;
and high-risk noncarriers, 0.5%). This frequency is similar to reported
results, including a recent prospective study where the prevalence of
ovarian/tubal/peritoneal cancers was 4.2% among BRCA1 mutation
carriers55 (Data Supplement). Use of more sensitive sectioning
protocols (longitudinal and transverse sectioning), combined with
growing diagnostic acumen (immunohistochemistry, focus on
fimbriae), suggests that our estimates of STIC and early tubal
neoplasia may prove low. Nonetheless, given the size and breadth
of ascertainment in GOG-0199, our estimates of prevalent neo-
plastic lesions at RRSO provide state-of-the-science evidence for
decision making and management.
Although women with suspicious symptoms were considered
ineligible, we cannot confirm strict protocol adherence to this require-
ment. Furthermore, abnormal or worrisome preoperative screening
tests were not considered exclusions, because of the nonspecificity of
positive testing in the general population.8 Overall, 9.6% of women
had abnormal CA-125 levels, TVU, or both, including 50% of women
with invasive ovarian/tubal cancer. Three of six women with invasive
BA
DC
Fig 2. Neoplastic lesions arising in fallopian tube. (A) Low-power (10 magnification) photomicrograph showing transition from benign fallopian tube epithelium
composed of uniform columnar cells (far right) to serous tubal intraepithelial cancer. (B) High-power (20 magnification) view of (A), demonstrating malignant-appearing
cells with pleomorphic nuclei. (C) Nodule of invasive high-grade serous cancer with suggested origin from fallopian tube epithelium (10 magnification). (D) High-power
(20 magnification) view of (C), showing solid sheets of tumor cells with suggestion of irregular gland formation; right side of image shows benign fallopian tube
epithelium.
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tubal cancer had abnormalities in CA-125 levels and/or TVU, whereas
all four women with STIC had normal results, suggesting that RRSO
offers protection that would be unachievable by screening high-risk
women. In addition, we identified two groups of women in whom
neoplasms were not found: noncarriers with normal CA-125 levels
and high-risk women age  42 years.
High CA-125 concentrations have been linked to detection of
cancer or dysplasia in prophylactic or diagnostic RRSO.59 In our
analysis, seven of 14 women with CA-125 levels  100 U/mL had
cancer (ovarian, n  4; peritoneal, n  2; tubal, n  1), only one of
whom had an abnormal TVU, which may partly explain why these
women were considered eligible for enrollment.
In this study, neoplasm prevalence was higher among older post-
menopausal women; none of the women with neoplasms was age
 42 years, consistent with prior data linking increasing age and risk.34
Although younger BRCA1 carriers are at markedly elevated relative
risk of ovarian/tubal cancer, their absolute risk up to age 40 years is
approximately  3%.60,61 Nonetheless, BRCA-related ovarian/tubal
neoplasms may occur at younger ages, particularly among BRCA1
mutation carriers. A recent report55 found that the estimated risk of
ovarian/tubal cancer before or at the time of RRSO among BRCA1
mutation carriers was 4% if surgery was delayed until age 40 years. The
absence of neoplasms among the youngest GOG-0199 participants
reflects the infrequency of such cases, the number of younger women
and the number of BRCA1 mutation carriers in this study, and the
probability that early-onset cancers may present symptomatically be-
fore ages at which RRSO is considered. Thus, in accordance with
standards of care, many BRCA1/2 mutation carriers opt for early
RRSO, prior to age-related increases in risk.62 Among noncarriers in
their 40s, whose ovarian cancer risk is lower but poorly defined,
development of chronic morbidity and mortality secondary to surgi-
cal menopause complicates this choice. Developing age-specific risk/
benefit models related to RRSO would be clinically useful.11-13 In
GOG-0199, microscopic neoplasms were found within the tubes and
ovaries, supporting prior recommendations to entirely submit these
tissues for histologic examination.27,63,64 Cytopathologic review of
peritoneal cytology did not affect detection of malignancy.
Eleven women in this trial presented with minimal disease, in-
cluding four with STICs, four with small invasive tubal cancers, two
with minimal ovarian involvement, and one with involvement of both
ovaries and the left fallopian tube, consistent with the view that the
fallopian tube is an important source of high-grade serous
cancers.14-17 As performance of RRSO with meticulous pathologic
assessment has become more common, detection of early neoplastic
lesions has risen, posing new challenges to optimal staging and man-
agement of women with minimal or noninvasive disease. In GOG-
0199, most large invasive cancers produced bulky ovarian disease and
were therefore classified as primary ovarian tumors when STIC was
not identified, which may have resulted in underestimation of the
number of tubal primaries.2,24-33,35-38,41,60
Bilateral salpingectomy with deferred oophorectomy has been
proposed as a temporizing prevention measure for high-risk individ-
uals, enabling premenopausal women to postpone oophorectomy
and maintain ovarian function for a longer time period.20 Developing
sensitive methods to exclude occult neoplastic lesions in retained
ovaries would strengthen the promise of this approach, as would
defining precisely the age-specific risks of ovarian, fallopian tube, and
breast cancers and chronic diseases secondary to hormone depriva-
tion among women with different risk factor profiles.18,65-66 Although
developing a unified pathogenetic model for high-grade serous ovar-
ian/tubal neoplasia is appealing, it is notable that only two cancers
were found among 403 high-risk noncarriers in GOG-0199, under-
scoring the need to determine whether managing these women simi-
larly to BRCA1/2 mutation carriers—as is currently done—is optimal.
Other data also suggest that risk of ovarian/tubal cancer in BRCA
mutation–negative familial breast cancer families is lower than among
mutation-positive women.67 STIC remains poorly described among
noncarriers, particularly without concurrent invasive fallopian
tube cancer.18
Six women had endometrial cancer at RRSO, including two
serous cancers (0.6%) in 326 BRCA1 mutation carriers and four
(1.0%) in 403 noncarriers. Serous endometrial cancer has been linked
to prior breast cancer, tamoxifen use, and, inconsistently, with BRCA1
mutation.68-70 Endometrial serous cancers may be associated with
lesions resembling STIC, perhaps representing independent primaries
or intramucosal spread from a single primary tumor.71 Given these
data, thorough microscopic endometrial examination is warranted
when hysterectomy is performed with RRSO.
Strengths of this study include its large sample size, prospective
design, recruitment from diverse practice settings, inclusion of muta-
tion-negative/strong family history–positive women, comprehensive
assessment of risk factors and BRCA1/2 mutation status, implemen-
tation of a standardized tissue processing protocol, and central pathol-
ogy review. To our knowledge, this is the largest study to date in which
the BRCA mutation status of all participants was known, all surgical
pathology material was handled via a predefined protocol, and a
rigorous, explicit effort was made to exclude symptomatic women
from study entry. Consequently, our results can be generalized with
confidence to different groups of women and practice settings.
Although GOG-0199 was designed to enroll asymptomatic high-
risk women, nearly 12% of participants had abnormal baseline tests,
raising concerns about whether these women were vaguely symptom-
atic or encouraged to undergo RRSO on that basis. However, com-
pared with the GOG-0199 screening arm, women in the surgical arm
did not have a significantly higher frequency of abnormal screening
tests (TVU and/or CA-125; 12.4% v 10.9%) or abnormal TVU (9.6%
v 8.9%), but they did have a slightly higher frequency of elevated
CA-125 levels (surgical arm, 4.0% v screening arm, 2.4%; P  .03).
These data argue against a strong referral bias toward RRSO. These
factors may have contributed to overestimation of the frequency of
asymptomatic prevalent cancer; however, this likely represents real-
world practice. Conversely, it is possible that some fallopian tubes and
ovaries were not entirely submitted for microscopy, despite that pro-
tocol requirement; this may have led to underestimation of neoplasm
prevalence. Incomplete ascertainment of STIC end points is impossi-
ble to eliminate, because even sectioning-blocked tissues at 2- to
3-mm thickness may miss focal lesions without serial sectioning. Fur-
thermore, some GOG-0199 participant cases may have been upstaged
after RRSO. Finally, GOG-0199 was not designed to assess the risk-
reducing value of hysterectomy, which was chosen electively by
participants and physicians, and indications for that procedure were
not collected.
In summary, this nonrandomized prospective clinical trial found
that 2.6% of women undergoing RRSO were diagnosed with ovarian/
tubal neoplasms, including 4.6% of BRCA1 mutation carriers, 3.5% of
BRCA2 mutation carriers, and 0.5% of noncarriers. Overall, 56% of
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women with ovarian/tubal neoplasia had STIC or stage I or II invasive
cancer, suggesting an improved prognosis compared with symptom-
atic presentation. Older, postmenopausal carriers of BRCA1/2 muta-
tions who presented with abnormal CA-125 serum levels or TVU were
more likely to have invasive neoplasms at RRSO, whereas women
lacking these features were at lower risk of neoplastic findings, espe-
cially if mutation negative. Our data suggest that assessing factors
associated with cancer at RRSO may enable improved, patient-specific
management decisions, which reflect complex considerations related
to cancer prevention, risks of non-neoplastic disease, and quality of life.
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GLOSSARY TERMS
BRCA1: a tumor suppressor gene known to play a role in re-
pairing DNA breaks. Mutations in this gene are associated with
increased risks of developing breast or ovarian cancer.
BRCA2: a tumor suppressor gene whose protein product is
involved in repairing chromosomal damage. Although structur-
ally different from BRCA1, BRCA2 has cellular functions similar
to BRCA1. BRCA2 binds to RAD51 to fix DNA breaks caused by
irradiation and other environmental agents. Also known as the
breast cancer 2 early onset gene.
CA-125 (cancer antigen 125): a protein produced by the
fallopian tubes, the endometrium, and the lining of the abdomi-
nal cavity (peritoneum). CA-125 is a tumor marker present in
higher than normal amounts in the blood and urine of patients
with certain cancers. Typically, women with ovarian cancer have
high levels of CA-125. Other conditions associated with elevated
levels of CA-125 include endometriosis, pancreatitis, pregnancy,
normal menstruation, and pelvic inflammatory disease. CA-125
levels may be used to help diagnose ovarian cancer and to deter-
mine whether these tumors are responding to therapy. The nor-
mal range for CA-125 is less than 35 U/mL and less than 20
U/mL for women who have been treated for ovarian cancer.
Women with ovarian cancer may show values higher than 65
U/mL.
logistic regression: a multivariable regression model in which the
log of the odds of a time-fixed outcome event (eg, 30-day mortality) or
other binary outcome is related to a linear equation.
mutation: a change of one base in a nucleotide sequence that may
result in a change in the amino acid sequence.
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Appendix
The following Gynecologic Oncology Group member institutions participated in the primary research study: Roswell Park Cancer
Institute, University of Alabama at Birmingham, Duke University Medical Center, Walter Reed Army Medical Center, Wayne State
University, University of Minnesota Medical School, Mount Sinai School of Medicine, University of Mississippi Medical Center,
Colorado Gynecologic Oncology Group, University of California at Los Angeles, University of Cincinnati, University of North Carolina
School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana
University School of Medicine, Wake Forest University School of Medicine, University of California Medical Center at Irvine, Rush-
Presbyterian-St Luke’s Medical Center, Magee Women’s Hospital, University of New Mexico, The Cleveland Clinic Foundation,
Washington University School of Medicine, Memorial Sloan Kettering Cancer Center, Cooper Hospital/University Medical Center,
Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Medical School, Fox Chase Cancer Center,
Women’s Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, Mayo Clinic,
Case Western Reserve University, Tampa Bay Cancer Consortium, Australia New Zealand Gynaecological Oncology Group Clinical
Trials Centre, Yale University, University of Wisconsin Hospital, Women and Infants Hospital, The Hospital of Central Connecticut, and
Community Clinical Oncology Program, and Warren G. Magnuson Clinical Center, National Institutes of Health.

















51 BRCA1 Post 2  3 Never 11 Negative Serous carcinoma Positive IIIA
67 BRCA1 Post 0 1 Prior 16 Negative Serous carcinoma Negative IA
44 Negative Pre 1 2 Never 14 Negative Mucinous carcinoma Negative IA
56 Negative Post 1 1 Unknown 36 Negative Mucinous carcinoma Negative IB
48 Negative Pre 1 2 Never 18 Negative Endometrioid carcinoma Negative I
51 Negative Post 1 0 Never 14 Negative Endometrioid carcinoma Negative IA
Abbreviations: CA-125, cancer antigen 125; RRSO, risk-reducing salpingo-oophorectomy; TVU, transvaginal ultrasound.
Sherman et al
© 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
